Search
Displaying 901–910 of 1069 results for “good fc coin websites Visit Buyfc26coins.com for latest FC 26 coins news..4sCp”
-
About Page
Roster of the Foundation Fighting Blindness Scientific Advisory Board
-
Clinical Trials that are open now
-
ARVO 2018: Dr. Henry Klassen Provides Update on jCyte Stem Cell Trials
Research NewsDr. Henry Klassen, jCyte co-founder and investigator at UC Irvine, provides an update on the clinical trials for an RP therapy derived from stem cells.
-
Optogenetic Therapy Takes First Step Forward in Clinical Trial
Research NewsRetroSense’s optogenetic therapy is designed to restore vision to people who are completely blind from retinal degenerative diseases such as retinitis pigmentosa by bestowing light sensitivity to retinal ganglion cells, which survive after photoreceptors, the cells that make vision possible, are lost.
-
Artist with Usher Syndrome Excited to Register on My Retina Tracker to Drive Retinal Research
Beacon StoriesArtist Dana Simon describes her experience with My Retina Tracker, a free and secure online registry for people with inherited retinal diseases.
-
ARVO 2016: High-School Sophomore Finds Gene Mutation in Family with Choroideremia
Research NewsAditya A. Guru, 16, used whole exome sequencing (WES), an innovative genetic-screening technology, to find the mutation.
-
Genetics 101: How Some Retinal Diseases are Inherited
Research NewsTo understand heredity, you have to know a little about genetics. Below is a review of the three major genetic-disease inheritance patterns.
-
The Power of Suggestion — Challenges of the Placebo Effect
Research NewsEven in a well-designed clinical trial, the placebo effect can rear its head.
-
Vision Improvements Reported in Choroideremia Gene Therapy Clinical Trial
Foundation NewsFive of six participants in the initial study group have sustained vision improvements in their treated eyes in dim settings.
-
Foundation Chairman, Gordon Gund, Interviewed on Forbes.com
Beacon StoriesThe driving force behind the Foundation’s considerable advances covers those, as well as other compelling subjects, during a 27-minute Q&A.
